Ascelia Pharma AB (publ) (ACE) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.137x

Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has a cash flow conversion efficiency ratio of -0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.66 Million ≈ $-1.69 Million USD) by net assets (Skr114.40 Million ≈ $12.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ascelia Pharma AB (publ) stock valuation for the company's overall valuation and market capitalisation.

Ascelia Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Ascelia Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ascelia Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their cash flow conversion efficiency. See ACE debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
KB SPAC 6 KQ:208640	-0.015x
Yorkton Equity Group Inc V:YEG	0.051x
Hindusthan National Glass & Industries Limited NSE:HINDNATGLS	-0.211x
Vantage Corp NYSE MKT:VNTG	0.077x
FATFISH GROUP LTD. F:1JU	N/A
Nanotech Indonesia Global Tbk PT JK:NANO	-0.010x
Bonk, Inc. NASDAQ:BNKK	-0.058x
Inter-Delta Tbk JK:INTD	-0.225x

Annual Cash Flow Conversion Efficiency for Ascelia Pharma AB (publ) (2017–2024)

The table below shows the annual cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024. View ACE stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr78.94 Million ≈ $8.50 Million	Skr-62.84 Million ≈ $-6.76 Million	-0.796x	+53.33%
2023-12-31	Skr74.33 Million ≈ $8.00 Million	Skr-126.79 Million ≈ $-13.64 Million	-1.706x	-146.30%
2022-12-31	Skr180.86 Million ≈ $19.46 Million	Skr-125.26 Million ≈ $-13.48 Million	-0.693x	-82.92%
2021-12-31	Skr307.83 Million ≈ $33.13 Million	Skr-116.56 Million ≈ $-12.54 Million	-0.379x	-4.51%
2020-12-31	Skr236.06 Million ≈ $25.40 Million	Skr-85.53 Million ≈ $-9.20 Million	-0.362x	-132.65%
2019-12-31	Skr237.06 Million ≈ $25.51 Million	Skr-36.92 Million ≈ $-3.97 Million	-0.156x	-41.74%
2018-12-31	Skr276.07 Million ≈ $29.71 Million	Skr-30.33 Million ≈ $-3.26 Million	-0.110x	+41.43%
2017-12-31	Skr111.73 Million ≈ $12.02 Million	Skr-20.96 Million ≈ $-2.26 Million	-0.188x	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$8.55 Million

Skr79.42 Million SEK

Market Cap Rank

#27545 Global

#602 in Sweden

Share Price

Skr0.63

Change (1 day)

+9.25%

52-Week Range

Skr0.48 - Skr3.85

All Time High

Skr900.24